Arovella Therapeutics Ltd
ASX:ALA

Watchlist Manager
Arovella Therapeutics Ltd Logo
Arovella Therapeutics Ltd
ASX:ALA
Watchlist
Price: 0.18 AUD -5.26% Market Closed
Market Cap: 189.3m AUD
Have any thoughts about
Arovella Therapeutics Ltd?
Write Note

P/E
Price to Earnings

-21.6
Current
-4.1
Median
22.3
Industry
Lower than median
Lower than industry value

Price to Earnings (P/E) ratio is a valuation multiple that compares a company’s market capitalization to its net income. It indicates the dollar amount an investor can expect to invest in a company in order to receive $1 of that company’s earnings.

P/E
-21.6
=
Market Cap
189.1m AUD
/
Net Income
-8.7m AUD
All Countries
Close
Market Cap P/E
AU
Arovella Therapeutics Ltd
ASX:ALA
189.1m AUD -21.6
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY -5 347 888.9
US
Eli Lilly and Co
NYSE:LLY
788.6B USD 107.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP -15 783.5
DK
Novo Nordisk A/S
CSE:NOVO B
3.4T DKK 37.5
US
Johnson & Johnson
NYSE:JNJ
384.8B USD 26.2
US
Merck & Co Inc
NYSE:MRK
259.4B USD 18.9
CH
Roche Holding AG
SIX:ROG
213.6B CHF 18.6
UK
AstraZeneca PLC
LSE:AZN
171.2B GBP 34.3
CH
Novartis AG
SIX:NOVN
183.5B CHF 13.1
US
Pfizer Inc
NYSE:PFE
160.4B USD 37.7
Earnings Growth
AU
Arovella Therapeutics Ltd
ASX:ALA
Average P/E: 36.7
Negative Multiple: -21.6
N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A
US
Eli Lilly and Co
NYSE:LLY
107.4
454%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A
DK
Novo Nordisk A/S
CSE:NOVO B
37.5
89%
US
Johnson & Johnson
NYSE:JNJ
26.2
-22%
US
Merck & Co Inc
NYSE:MRK
18.9
7 426%
CH
Roche Holding AG
SIX:ROG
18.6
30%
UK
AstraZeneca PLC
LSE:AZN
34.3
175%
CH
Novartis AG
SIX:NOVN
13.1
19%
US
Pfizer Inc
NYSE:PFE
37.7
712%

P/E Forward Multiples

Forward P/E multiple is a version of the P/E ratio that uses forecasted net income for the P/E calculation. 1-Year, 2-Years, and 3-Years forwards use net income forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
P/E
-17.8
2-Years Forward
P/E
N/A
3-Years Forward
P/E
N/A

See Also

Discover More